BidaskClub Downgrades Celyad SA (CYAD) to Hold

Celyad SA (NASDAQ:CYAD) was downgraded by research analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued on Tuesday, July 11th.

Separately, ValuEngine upgraded shares of Celyad SA from a “sell” rating to a “hold” rating in a research note on Thursday, June 29th.

Celyad SA (CYAD) remained flat at $37.00 on Tuesday. The stock had a trading volume of 96 shares. Celyad SA has a 52 week low of $16.31 and a 52 week high of $48.93. The company’s market capitalization is $352.24 million. The company’s 50 day moving average is $42.73 and its 200-day moving average is $31.01.

TRADEMARK VIOLATION WARNING: “BidaskClub Downgrades Celyad SA (CYAD) to Hold” was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at https://sportsperspectives.com/2017/07/24/celyad-sa-cyad-cut-to-hold-at-bidaskclub-updated.html.

A hedge fund recently raised its stake in Celyad SA stock. Victory Capital Management Inc. increased its stake in Celyad SA (NASDAQ:CYAD) by 6.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 374,493 shares of the company’s stock after buying an additional 22,600 shares during the period. Victory Capital Management Inc. owned about 3.93% of Celyad SA worth $9,988,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 4.25% of the company’s stock.

About Celyad SA

Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company’s product, C-Cure, allows the differentiation of a patient’s own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle.

Receive News & Ratings for Celyad SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celyad SA and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply